RESPECT trial is designed to provide the kind of Level 1 evidence EndoGastic Solutions needs to persuade payers and physicians of the benefits of the EsophyX GERD-repair device. Cordis and Aptus Endosystems release new data at the Vascular Interventional Advances (VIVA) 2013 annual meeting in Las Vegas.
EndoGastric Solutions Inc. announced Oct. 8 that it has completed enrollment for the Randomized EsophyX vs. Sham/Placebo Controlled Trial (RESPECT
) with more than the originally planned 120 patients. RESPECT is designed to identify the appropriate selection criteria for patients most likely to benefit from the transoral incisionless fundoplication (TIF)...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
